Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study — DART  

Skin Disease, Infectious Clinical Trial

Official title: DART: "Sivextro® in Acute Bacterial Skin anD Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global ObseRvational STudy."

Status Terminated

Clinical Trial Summary

This open-label, prospective, multi-center, non-interventional, observational, parallel cohort study intended to provide real life data on the treatment duration, effectiveness and safety of tedizolid and linezolid when treating ABSSSI hospitalized patients in a real practice setting.

Clinical Trial Description

The primary objective of this study was to assess the treatment duration in the real life in 2 cohorts consisting of patients treated by 200 mg once daily IV/PO tedizolid or treated by 600 mg twice daily IV/PO (intravenous/per oral) linezolid. ;

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Skin Disease, Infectious
• Skin Diseases
• Skin Diseases, Bacterial
• Skin Diseases, Infectious

• NCT number: NCT02991131
• Study type: Observational
• Source: Bayer
• Status: Terminated
• Start date: December 17, 2016
• Completion date: November 21, 2018